Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

被引：0

作者：

Das Thakur, Meghna ^{[1
]}

Fisher, Rosalie ^{[2
]}

Salangsang, Fernando ^{[1
]}

Landman, Allison ^{[3
]}

Sellers, William ^{[4
]}

Pryer, Nancy ^{[1
]}

Levesque, Mitchell Paul ^{[5
]}

Dummer, Reinhard ^{[5
]}

Gore, Martin ^{[2
]}

Larkin, James ^{[2
]}

McMahon, Martin ^{[3
]}

Stuart, Darrin ^{[1
]}

机构：

[1] Novartis, Emeryville, CA USA

[2] Royal Marsden Hosp, London SW3 6JJ, England

[3] UCSF, San Francisco, CA USA

[4] Novartis, Cambridge, MA USA

[5] Univ Zurich Hosp, CH-8091 Zurich, Switzerland

来源：

CANCER RESEARCH | 2013年 / 73卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2013-LB-144

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB144

引用

页数：1

共 50 条

[31] Hypoxia-Driven Bypass Mechanism of Innate Resistance to Vemurafenib in Melanoma
Qin, Yong
Chattopadhyay, Chandrani
Hashimoto, Yuuri
Ekmekcioglu, Suhendan
Greene, Victoria R.
Grimm, Elizabeth A.
FREE RADICAL BIOLOGY AND MEDICINE, 2013, 65 : S24 - S24
[32] The role of beta-catenin in resistance of melanoma cells toward vemurafenib
Sinnberg, T.
Makino, E.
Beck, D.
Niessner, H.
Meier, F.
Garbe, C.
Schittek, B.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 93 - 93
[33] Vemurafenib-induced RhoB expression leads to melanoma cell resistance
Delmas, Audrey
Cherier, Julia
Medale-Giamarchi, Claire
Pradines, Anne
Favre, Gilles
CANCER RESEARCH, 2013, 73 (08)
[34] Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms
Monsma, David J.
Cherba, David M.
Eugster, Emily E.
Dylewski, Dawna L.
Davidson, Paula T.
Peterson, Chelsea A.
Borgman, Andrew S.
Winn, Mary E.
Dykema, Karl J.
Webb, Craig P.
MacKeigan, Jeffrey P.
Duesbery, Nicholas S.
Nickoloff, Brian J.
Monks, Noel R.
AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (04): : 1507 - +
[35] Effect of antiestrogens on leukemic cells: Relevance to drug resistance.
Dvilansky, A
Atlas, L
Nathan, I
EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 506 - 506
[36] BCR-ABL kinase dynamics in drug resistance.
Azam, M
Nardi, V
Shakespeare, W
Latek, RR
Bohacek, R
Veach, D
Clarkson, B
Sawyer, TK
Daley, GQ
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9021S - 9022S
[37] BRAF inhibitor (vemurafenib) resistance confers sensitivity to arginine deprivation in melanoma
Li, Ying-Ying
Wu, Chunjing
Chen, Shu-Mei
Wangpaichitr, Medhi
You, Min
Spector, Seth
Feun, Lynn G.
Kuo, Macus T.
Savaraj, Niramol
CANCER RESEARCH, 2014, 74 (19)
[38] The role of the Hippo/YAP pathway in cancer drug resistance.
Bivona, Trever
MOLECULAR CANCER RESEARCH, 2020, 18 (08) : 17 - 17
[39] The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
Das Thakur, Meghna
Stuart, Darrin D.
CANCER RESEARCH, 2013, 73 (20) : 6106 - 6110
[40] Nongenetic Mechanisms of Drug Resistance in Melanoma
Rebecca, Vito W.
Herlyn, Meenhard
ANNUAL REVIEW OF CANCER BIOLOGY, VOL 4, 2020, 4 : 315 - 330

← 1 2 3 4 5 →